SCHEMBL5409792

SCHEMBL5409792

COc1ccc(Oc2cccc(Cn3nc4c(c3-c3cccc(N)c3)c(=O)n(C)c(=O)n4CC(C)C)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.45
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TSHR P16473 2/20 0.40
TP53 P04637 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
PDE1A P54750 2/20 0.39
PDE1B Q01064 2/20 0.39
PDE1C Q14123 2/20 0.39
FAAH O00519 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
BTK Q06187 1/20 0.38
PCSK9 Q8NBP7 3/20 0.38
USP2 O75604 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5395878 0.88 HIF1A (0.43) HIF1AMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL5398457 0.88 HIF1A (0.43) HIF1AMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL5400118 0.84 MTNR1B (0.43) HIF1AMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL5395315 0.83 HIF1A (0.44) HIF1AMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL5411122 0.83 HIF1A (0.44) HIF1AMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL5407727 0.83 PDE1A (0.45) HIF1AMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL5411099 0.82 HIF1A (0.43) HIF1AMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL5410385 0.79 HIF1A (0.40) HIF1AMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL5411404 0.77 PDE1A (0.39) MEN1ALDH1A1KMT2ASMN1; SMN2TSHR
SCHEMBL5393436 0.76 NPBWR1 (0.49) MEN1KMT2ACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285558-B2 Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections ASTRAZENECA AB (SE) 2007-10-23 US disclosed
US-20040254183-A1 Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections ASTRAZENECA AB (SE) 2004-12-16 US disclosed
EP-1412355-A1 NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS AstraZeneca AB (SE) 2004-04-28 EP disclosed
WO-2003002567-A1 NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS ASTRAZENECA AB (SE) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254183-A1 Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections DPYD, HPGDS, PGC HIF1A 1678/4885MEN1 4216/4885ALDH1A1 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.